Novartis (NVS) announced that the FDA has approved its ARZERRA (ofatumumab), in combination with the chemo agents fludarabine and cyclophosphamide, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). ARZERRA was previously approved for the treatment of CLL patients who have not responded to fludarabine and Sanofi's (SNY) LEMTRADA (alemtuzumab), in treatment-naive CLL patients not treated with fludarabine and maintenance treatment of CLL in partial/complete responders treated with at least two prior lines of therapy.